What is the significance of an elevated parathyroid hormone level of 111 pg/mL with a normal ionized calcium of 1.26 mmol/L, and how should it be evaluated and managed?

Elevated PTH with Normal Ionized Calcium: Secondary Hyperparathyroidism Until Proven Otherwise

Your laboratory values—PTH 111.3 pg/mL with ionized calcium 1.26 mmol/L (normal range 1.15–1.36 mmol/L)—represent normocalcemic hyperparathyroidism, and the overwhelming priority is to systematically exclude all secondary causes before considering primary hyperparathyroidism. 1

Immediate Diagnostic Algorithm

Step 1: Rule Out the Three Most Common Secondary Causes

Vitamin D deficiency is the single most frequent cause of normocalcemic PTH elevation and must be excluded first. 1, 2

• Measure 25-hydroxyvitamin D immediately—a level <20 ng/mL (<50 nmol/L) confirms vitamin D deficiency as the driver of elevated PTH 1
• Vitamin D-replete individuals have PTH concentrations approximately 20% lower than those with unknown vitamin D status 1
• Do not diagnose primary hyperparathyroidism until 25-hydroxyvitamin D is documented >20 ng/mL 1

Assess dietary calcium intake—inadequate intake (<1,000–1,200 mg/day) causes physiologic PTH elevation 1, 2

• Confirm the patient is consuming age-appropriate calcium (1,000–1,200 mg/day for adults) 1
• Low calcium intake mimics secondary hyperparathyroidism and must be corrected before further evaluation 1

Evaluate renal function—chronic kidney disease is a key differential 1

• Measure serum creatinine and calculate eGFR—PTH rises when eGFR falls below 60 mL/min/1.73 m² 1
• An eGFR <60 mL/min/1.73 m² indicates CKD-related secondary hyperparathyroidism, not primary disease 1

Step 2: Exclude Medication-Induced PTH Elevation

Review all medications that can stimulate PTH secretion: 2

• Thiazide diuretics can cause hypercalcemia but may also elevate PTH independently
• Lithium shifts the calcium set-point and increases PTH
• Biotin supplementation interferes with PTH immunoassays—discontinue biotin ≥72 hours before repeat PTH measurement 1

Step 3: Confirm Persistent Elevation with Proper Sampling

PTH has substantial biological variation (≈20% in healthy individuals), so a single elevated value is insufficient for diagnosis. 1

• Repeat PTH measurement in EDTA plasma (not serum) kept at 4°C—PTH is most stable under these conditions 1
• A change >54% between measurements is required to be clinically meaningful rather than random fluctuation 1
• Use assay-specific reference ranges—PTH assays vary by up to 47% between different generations 1

Step 4: Consider Demographic and Physiologic Modifiers

Age, race, and BMI all influence baseline PTH concentrations: 1

• In adults >60 years, PTH naturally rises due to gradual GFR decline—use age-adjusted reference ranges 1
• Black individuals have higher baseline PTH than White individuals—consider race-specific intervals 1
• Higher BMI correlates positively with PTH levels—obese patients typically have modestly elevated PTH 1

When to Diagnose Normocalcemic Primary Hyperparathyroidism (NPHPT)

NPHPT should be diagnosed only after rigorous exclusion of all secondary causes and requires persistently elevated PTH with consistently normal calcium. 1, 2

Diagnostic Criteria for NPHPT

• 25-hydroxyvitamin D >20 ng/mL (>50 nmol/L) 1
• Adequate dietary calcium intake (≥1,000–1,200 mg/day) 1
• Normal renal function (eGFR ≥60 mL/min/1.73 m²) 1
• No interfering medications (thiazides, lithium, biotin) 2
• Persistently elevated PTH on repeat measurement (>54% change threshold) 1

Additional Workup for Confirmed NPHPT

If all secondary causes are excluded, proceed with target-organ assessment: 1

• 24-hour urine calcium or spot urine calcium/creatinine ratio—hypercalciuria >300 mg/24 hours indicates renal involvement and is a surgical indication 1
• Bone density scan (DEXA)—osteoporosis (T-score ≤-2.5 at any site) is a surgical indication 1
• Renal ultrasonography—assess for nephrocalcinosis or kidney stones 1

Management Approach

If Secondary Hyperparathyroidism Is Confirmed

Treat the underlying cause: 1

• For vitamin D deficiency: Supplement with ergocalciferol or cholecalciferol to achieve 25-hydroxyvitamin D >20 ng/mL, then recheck PTH 1
• For inadequate calcium intake: Increase dietary calcium to 1,000–1,200 mg/day (total elemental calcium should not exceed 2,000 mg/day) 1
• For CKD-related secondary hyperparathyroidism: Refer to nephrology for phosphate management, vitamin D analogs, and calcimimetics 3

If NPHPT Is Confirmed

NPHPT is not benign—it carries a risk profile comparable to hypercalcemic primary hyperparathyroidism. 1

Refer to endocrinology and an experienced parathyroid surgeon for evaluation if any of the following are present: 1

• Severe hypercalciuria (>300 mg/24 hours)—high risk of nephrocalcinosis 1
• Osteoporosis (T-score ≤-2.5) 1
• Nephrolithiasis or nephrocalcinosis 1
• Impaired kidney function (eGFR <60 mL/min/1.73 m²) 1
• Disabling neuropsychiatric symptoms (refractory depression, cognitive impairment, "brain fog") 1
• Patient preference for definitive treatment 1

For patients who do not meet surgical criteria or decline surgery: 1

• Maintain 25-hydroxyvitamin D >20 ng/mL with cholecalciferol or ergocalciferol 1
• Ensure normal calcium intake (1,000–1,200 mg/day) 1
• Monitor serum calcium every 3 months 1
• Repeat bone density scan every 1–2 years 1

Critical Pitfalls to Avoid

Do not order parathyroid imaging (sestamibi, ultrasound) before confirming the biochemical diagnosis—imaging is for surgical planning, not diagnosis 1

Do not prescribe calcitriol or active vitamin D analogs in suspected primary hyperparathyroidism—they increase intestinal calcium absorption and can precipitate hypercalcemia 1

Do not attribute normocalcemic PTH elevation to primary hyperparathyroidism without first confirming adequate vitamin D status and calcium intake—these reversible factors are the most common contributors 1

Recognize that a single PTH measurement is insufficient—biological variation requires repeat testing to confirm persistence 1